Anticoagulation: ($2.5 Billion) Oral Heparin

• Market growing ~ 15% annually

• UFH: Indication

  • Exploring niche indications in addition to prophylaxis of Deep Vein Thrombosis (DVT)
  • Validated cGMP tablet and capsule in-house facility

• Identified 3 formulations to test in clinic with improved performance over December prototype

• Demonstrated the safety profile of oral drug delivery technology and effectiveness of oral form of  UF heparin in PROTECT

Previous slide

Next slide

Back to first slide

View graphic version